RT Book, Section
A1 Wein, Richard O.
A1 O'Leary, Miriam
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145758703
T1 Cancer of the Unknown Primary
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK hemonc.mhmedical.com/content.aspx?aid=1145758703
RD 2024/04/19
AB Carcinoma  of  unknown  primary  origin  (CUPO)  is  estimated  to  represent  between  3%  and  5%  of  all  head  and  neck  cancer  presentations,  and  can  pose  a  challenge  in  assessment  when  diagnosed.1  Metastatic  carcinoma  from  an  occult  upper  aerodigestive  tract  (UADT)  source  carries  a  different  prognosis  than  cancers  metastatic  to  the  neck  from  an  infraclavicular  source.  When  patients  have  a  primary  site  identified,  they  benefit  from  the  ability  to  offer  site-specific  therapy  that  can  reduce  the  morbidity  of  treatment.  Identification  of  a  primary  site  also  improves  the  capacity  for  prognostic  counseling  while  facilitating  the  long-term  assessment  for  recurrence.  With  advances  in  diagnostic  imaging,  development  of  new  surgical  techniques,  and  the  expansion  of  immunohistochemical  (IHC)  and  gene  expression  studies  for  tissue  specimens,  the  assessment  of  CUPO  patients  continues  to  evolve.